Navigation Links
Tanabe Research Labs Enters R&D Partnership with Anaphore to Develop Novel Protein Pharmaceuticals for Autoimmune Disorders
Date:12/13/2010

g a new class of protein therapeutics for immune-system disorders."

About Anaphore

Anaphore is developing a new class of protein pharmaceuticals to address significant unmet medical needs for patients with serious diseases. The company's Atrimer technology platform originates in tetranectin, a human plasma protein of trivalent structure. Atrimers™ potentially offer biological, manufacturing, and commercial advantages over currently marketed therapies. Atrimer protein therapeutics are protected by intellectual property including multiple patent families. Anaphore's initial therapeutic focus is immunology and oncology. In collaboration with select partners, Anaphore is committed to realizing the full promise of Atrimers™ against targets in a wide range of therapeutic areas, including rare diseases.

http://www.anaphore.com.

About Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation is a research-driven pharmaceutical company based in Japan, specializing in research, development and marketing of globally competitive pharmaceutical products focused on the immune and inflammatory field, and the metabolism and cardiovascular field.  Mitsubishi Tanabe Pharma contributes to the healthier lives of people around the world through the creation of pharmaceuticals.

http://www.mt-pharma.co.jp/e

About Tanabe Research Laboratories U.S.A., Inc.

TRL is an independent subsidiary of Mitsubishi Tanabe Pharma Corporation whose role is to discover and develop potential biological drug candidates for therapy in autoimmune diseases.

Currently, TRL's efforts will be directed towards antibody and antibody related research to target specific immune cells and soluble factors, as well as investigating new meth
'/>"/>

SOURCE Tanabe Research Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
4. Researchers at Cleveland Clinic Identify Site of Dysfunction in HDL, Carrier of Good Cholesterol
5. Video: New Research Discovers Independent Brain Networks Control Human Walking
6. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
7. Cleveland Clinic Researchers Identify Mechanism Behind Platelet Function and Potentially Fatal Blood Clot Formation
8. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
9. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
10. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
11. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... May 29, 2015 Educating the community ... Association for the Advancement of Wound Care (AAWC), ... support from AAWC,s corporate partners, the Association provides ... on the AAWC website at http://aawconline.org/education-for-the-generalist/ . ... pathway with links to various CME/CEU educational programs. ...
(Date:5/28/2015)... May 28, 2015 ... the addition of Jain PharmaBiotech,s new report  ...  to their offering.       (Logo: ... gene silencing involves the use of double ... this material is processed into short 21-23 ...
(Date:5/28/2015)... , May 28, 2015 The controversy ... )  in hysterectomies and myomectomies (procedures to remove uterine ... the FBI is investigating Johnson & Johnson,s Ethicon, ... of the devices. According to the report published ... th , the FBI is trying to determine ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 2Global RNAi Market Report 2015-2024 - Technologies, Markets and Companies 3Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 2Power Morcellator Attorneys at Bernstein Liebhard LLP Comment on Report That FBI Is Investigating Ethicon Morcellators 3
... VIRGINIA BEACH, Va., July 8, 2011 The Amerigroup ... check to the Rx Partnership to benefit the Rockbridge ... is an organization that works to provide uninsured Virginians ... as a broker to access and distribute free bulk ...
... Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III ... patients taking Afinitor® (everolimus) tablets* experienced a 50% ... subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors ... the largest prospective clinical trial to date in ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 2Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 3Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 4Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 5Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 6Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 7Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 8Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 9Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 10Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 11Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 12Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis 13
(Date:5/29/2015)... Montclair, NJ (PRWEB) May 30, 2015 ... and ever changing local and federal regulations, we ... needs of their patients who are suffering from ... regulations,” says Srinivas Nalamachu, MD, professor of rehabilitation ... Research Institute in Overland Park, Kansas. , A ...
(Date:5/29/2015)... Washington, PA (PRWEB) May 29, 2015 ... ” quiz-based learning in 14 medical specialties, now offers ... includes a wide spectrum of rheumatology disorders ranging from ... Alfred Saint Jacques, editorial director of MDLinx, and Caroline ... excited about the impact it will have on the ...
(Date:5/29/2015)... May 29, 2015 The science of ... last decade. New and more efficient methods of FUE hair ... balding patients. One of the most cutting edge hair transplant ... Restoration is the technique of extracting hair from the beard ... are performed to correct male pattern baldness. Beard ...
(Date:5/29/2015)... Jan Wooden Howse lost her husband and her son, ... God does no wrong. , It’s fitting, then, that her ... titled “God Does No Wrong.” It focuses on what happens ... , “My story has a positive message about channeling ... productive, something healing,” Howse said. , “God Does No Wrong” ...
(Date:5/29/2015)... New York, New York (PRWEB) May 29, 2015 ... and distributor of patented products, announces that it has ... Chat Room, a technology patent that aims to let ... various industry experts in real time. , "This is ... Expert Chat Room " said Scott J. Cooper, CEO ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... American College of Physicians (ACP) and the Infectious Diseases ... on the importance of adult vaccination against an increasing ... by 17 other medical societies representing a range of ... Control and Prevention, 95 percent of vaccine-preventable diseases occur ...
... 19 NuVasive, Inc. (Nasdaq: NUVA ), a ... surgical treatments for the spine, announced today that Alex Lukianov, ... the 20th Annual Piper Jaffray Health Care Conference at The ... 10:30 a.m. ET. , , ...
... Microsoft Corp. today,announced that Blue Cross ... private health carrier, has saved nearly a ... system. Implemented to overhaul,incentive compensation and agent ... VUE Compensation Management, a Microsoft .NET,Framework-based application, ...
... of URAC,s Comprehensive Wellness Accreditation standards , ... announced today that its Board of Directors has approved ... These innovative standards reinforce and support the commitment ... health and productivity of America,s workforce. Comprehensive Wellness ...
... and,president of Ellie,s Meditative Movements, announces the arrival of ... new direction and fulfillment. Meditative,Movements(TM) is the companion ... , Ms. Peterson ... challenge,of raising three children alone, then explains the victory ...
... Erosion and a Dearth of Promising Emerging Therapies Will ... Report from Decision Resources , , ... Decision Resources, one of the world,s leading research ... that, owing to their improvements in safety and efficacy, ...
Cached Medicine News:Health News:Medical societies: Adults need vaccines 2Health News:NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference 2Health News:NuVasive to Present at 20th Annual Piper Jaffray Health Care Conference 3Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 2Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 3Health News:Blue Cross and Blue Shield of Vermont Saves Nearly a Half-Million Dollars with a Microsoft Partner Compensation Management Solution 4Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 2Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 3Health News:URAC Announces Accreditation Standards for Comprehensive Wellness Programs 4Health News:Meditative Movements(TM), State-of-the-Art Fitness Guidebook, Now Available 2Health News:Uptake of Next-Generation Antifungals Has Intensified Competition in the Severe Fungal Infections Drug Market 2
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
... Antibody (IgG) Test is a semiquantitative enzyme ... significant IgG antibodies to M. pneumoniae between ... test should not be used for specimens ... (IgM) Test and is not intended for ...
... Test is a qualitative enzyme immunoassay ... Epstein-Barr virus capsid antigen (EBV-VCA), Epstein-Barr ... and Toxoplasma. When used in conjunction ... aid in the serodiagnosis of infectious ...
... Test is an enzyme immunoassay ... the presence of antibodies to ... and herpes simplex virus in ... to indicate previous or current ...
Medicine Products: